Compare AstraZeneca plc (AZN) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Micron Technology, Inc. — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while Micron Technology, Inc. trades at $917.31 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 4× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | MU | |
|---|---|---|
Market Cap | $248.14B | $980.90B |
Sector | Health | Technology |
52-Week High | $209.48 | $1.21K |
52-Week Low | $147.06 | $115.79 |
Enterprise Value | $275.41B | $961.25B |
Dividend Yield | 2.01% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Micron Technology (MU) trades at $921.01, up 6.97% in 24 hours, with strong earnings beats in recent quarters and robust profitability metrics. Technical indicators show a bearish short-term signal, with the stock near resistance at $877. The company exhibits exceptional gross margins of 72.57% and net income margin of 55.91%, supported by surging memory demand and strategic customer agreements.
Outlook remains positive due to AI-driven memory demand and locked-in revenues, but risks include cyclical industry pressures and competitive threats. Analyst consensus is strongly bullish with an average price target of $1,540, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
